Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574847 · ClinicalTrials.gov registry record · Phase 4
Responses of Myocardial Ischemia to Escitalopram Treatment
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
NCT00574847: Completed Phase 4 study, sponsored by Duke University.
NCT00574847 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 127 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574847, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
Study Summary
Depression is commonly seen in patients with cardiovascular disorders. In recent studies it has been shown that mild to moderate depression symptoms were associated with increased likelihood of mental stress-induced myocardial ischemia (MSIMI), which is a risk factor of poor cardiac outcome. In this project, the investigators aim to assess the treatment of mental stress-induced myocardial ischemia in ischemic heart disease patients with mild to moderate depressive symptoms. This study is a six-week double-blind placebo controlled study to examine the effects of escitalopram on mental stress-induced myocardial ischemia. This study will look to show that patients with ischemic heart disease who are treated with escitalopram will exhibit a significant improvement of MSIMI at the end of week 6 compared to patients receiving placebo.
Primary Outcome
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks.
Interventions
- DRUG Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2006-09 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
What the finished NCT00574847 record still lists
NCT00574847 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00574847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00574847 about?
NCT00574847 is a clinical study titled "Responses of Myocardial Ischemia to Escitalopram Treatment". Depression is commonly seen in patients with cardiovascular disorders. In recent studies it has been shown that mild to moderate depression symptoms were associated with increased likelihood of mental stress-induced myocardial ischemia (MSIMI), which is a risk factor of poor cardiac outcome. In this...
What is the current status of trial NCT00574847?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2006-09. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00574847?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00574847?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00574847's enrollment target sits among peer trials
127 639th of 2000 higher than 1,355 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia